The OSHA is accepting applications for its FY 2026 Susan Harwood Training Grant Program, focusing on targeted topic training to improve workplace safety. Eligible applicants include nonprofits and educational institutions, with a deadline of July 31, 2026. This program supports innovative training programs that address specific safety and health hazards.
Why it matters. With a CFDA number of 17.502, this grant is crucial for organizations aiming to enhance safety standards in high-risk environments.
Our readExpect strong competition for these grants as organizations rush to secure funding for pressing safety initiatives.
Source · Grants.gov
FEMA is offering funding through the Homeland Security National Training Program, aimed at enhancing training for emergency responders. The application deadline is July 31, 2026, and eligible applicants include state and local governments and nonprofits. This program emphasizes preparedness and response capabilities in disaster situations.
Why it matters. With a CFDA number of 97.005, this opportunity aligns with federal priorities to bolster community resilience and safety.
Our readThis grant is a prime opportunity for local governments and nonprofits to enhance their emergency response training initiatives.
Source · Grants.gov
The National Cancer Institute (NCI) seeks research co-development partners for a novel viral peptide-based therapeutic aimed at preventing and treating hepatocellular carcinoma (HCC). This initiative highlights the NCI's focus on innovative cancer treatments and the potential for collaboration. Interested parties should act quickly to engage with this opportunity.
Why it matters. Interested parties should act quickly to engage with this opportunity.
Our readThis licensing opportunity signals a push towards innovative cancer therapies; expect interest from biotech startups.
Source · Federal Register
The National Cancer Institute is also seeking partners for developing chimeric virus-like particle (VLP) vaccines aimed at preventing HTLV-1 infection. This opportunity reflects the NCI's commitment to addressing viral infections that can lead to serious health issues. Interested organizations should consider this as a pathway to innovate in vaccine development.
Why it matters. This is particularly relevant for organizations in the biotech and pharmaceutical sectors focused on infectious diseases.
Our readThe potential for collaboration in vaccine development is significant; expect interest from established and emerging biotech firms.
Source · Federal Register